{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:40:10Z","timestamp":1780638010451,"version":"3.54.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41397-018-0052-2","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T20:49:55Z","timestamp":1537562995000},"page":"286-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"19","author":[{"given":"Wimonchat","family":"Tangamornsuksan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4439-0560","authenticated-orcid":false,"given":"Manupat","family":"Lohitnavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,21]]},"reference":[{"key":"52_CR1","first-page":"730","volume":"16","author":"TH Maren","year":"1977","unstructured":"Maren TH, Haywood JR, Chapman SK, Zimmerman TJ. The pharmacology of methazolamide in relation to the treatment of glaucoma. Invest Ophthalmol Vis Sci. 1977;16:730\u201342.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"52_CR2","unstructured":"PubChem Compound Database [Internet]. National Center for Biotechnology Information. [cited December 21, 2017]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/4100 ."},{"key":"52_CR3","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","volume":"331","author":"JC Roujeau","year":"1994","unstructured":"Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272\u201385.","journal-title":"N Engl J Med"},{"issue":"1","key":"52_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","volume":"54","author":"Marianne Lerch","year":"2017","unstructured":"Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clinical reviews in allergy & immunology. 2018;54:147\u201376.","journal-title":"Clinical Reviews in Allergy & Immunology"},{"key":"52_CR5","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamadermatol.2017.3957","volume":"153","author":"EN Ergen","year":"2017","unstructured":"Ergen EN, Hughey LC. Stevens-Johnson syndrome and toxic epidermal necrolysis. JAMA Dermatol. 2017;153:1344.","journal-title":"JAMA Dermatol"},{"key":"52_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","volume":"209","author":"JC Roujeau","year":"2005","unstructured":"Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209:123\u20139.","journal-title":"Toxicology"},{"key":"52_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40257-015-0158-0","volume":"16","author":"RP Dodiuk-Gad","year":"2015","unstructured":"Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475\u201393.","journal-title":"Am J Clin Dermatol"},{"issue":"Suppl 4","key":"52_CR8","first-page":"995","volume":"24","author":"A Oliveira","year":"2011","unstructured":"Oliveira A, Sanches M, Selores M. Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Med Port. 2011;24(Suppl 4):995\u20131002.","journal-title":"Acta Med Port"},{"key":"52_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1590\/abd1806-4841.20176610","volume":"92","author":"LB Arantes","year":"2017","unstructured":"Arantes LB, Reis CS, Novaes AG, Carvalho MR, Gottems LBD, Novaes M. Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiological and clinical outcomes analysis in public hospitals. Bras Dermatol. 2017;92:661\u20137.","journal-title":"Bras Dermatol"},{"key":"52_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2217\/pme.10.46","volume":"7","author":"M Bharadwaj","year":"2010","unstructured":"Bharadwaj M, Illing P, Kostenko L. Personalized medicine for HLA-associated drug-hypersensitivity reactions. Pers Med. 2010;7:495\u2013516.","journal-title":"Pers Med"},{"key":"52_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","volume":"18","author":"C Lonjou","year":"2008","unstructured":"Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharm Genom. 2008;18:99\u2013107.","journal-title":"Pharm Genom"},{"key":"52_CR12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00251-017-1007-5","volume":"69","author":"PT Illing","year":"2017","unstructured":"Illing PT, Purcell AW, McCluskey J. The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions. Immunogenetics. 2017;69:617\u201330.","journal-title":"Immunogenetics"},{"key":"52_CR13","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","volume":"149","author":"W Tangamornsuksan","year":"2013","unstructured":"Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2013;149:1025\u201332.","journal-title":"JAMA Dermatol"},{"key":"52_CR14","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/archopht.1982.01030040431012","volume":"100","author":"BJ Mondino","year":"1982","unstructured":"Mondino BJ, Brown SI, Biglan AW. HLA antigens in Stevens-Johnson syndrome with ocular involvement. Arch Ophthalmol (Chic, Ill: 1960). 1982;100:1453\u20134.","journal-title":"Arch Ophthalmol (Chic, Ill: 1960)"},{"key":"52_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1399-0039.1986.tb00491.x","volume":"28","author":"JC Roujeau","year":"1986","unstructured":"Roujeau JC, Bracq C, Huyn NT, Chaussalet E, Raffin C, Duedari N. HLA phenotypes and bullous cutaneous reactions to drugs. Tissue Antigens. 1986;28:251\u20134.","journal-title":"Tissue Antigens"},{"key":"52_CR16","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1001\/archderm.1987.01660330082014","volume":"123","author":"JC Roujeau","year":"1987","unstructured":"Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol. 1987;123:1171\u20133.","journal-title":"Arch Dermatol"},{"key":"52_CR17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/FPC.0000000000000153","volume":"25","author":"T Kongpan","year":"2015","unstructured":"Kongpan T, Mahasirimongkol S, Konyoung P, Kanjanawart S, Chumworathayi P, Wichukchinda N, et al. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharm Genom. 2015;25:402\u201311.","journal-title":"Pharm Genom"},{"key":"52_CR18","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.2217\/pgs.15.128","volume":"16","author":"S Rufini","year":"2015","unstructured":"Rufini S, Ciccacci C, Politi C, Giardina E, Novelli G, Borgiani P. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction. Pharmacogenomics. 2015;16:1989\u20132002.","journal-title":"Pharmacogenomics"},{"key":"52_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-39","volume":"5","author":"T Harr","year":"2010","unstructured":"Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"52_CR20","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3390\/ijms17111890","volume":"17","author":"Shih-Chi Su","year":"2016","unstructured":"Su SC, Hung SI, Fan WL, Dao RL, Chung WH. Severe cutaneous adverse reactions: the pharmacogenomics from research to clinical implementation. Int J Mol Sci. 2016;17:1890.","journal-title":"International Journal of Molecular Sciences"},{"key":"52_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/tan.13183","volume":"91","author":"AJ Redwood","year":"2018","unstructured":"Redwood AJ, Pavlos RK, White KD, Phillips EJ. HLAs: key regulators of T-cell-mediated drug hypersensitivity. HLA. 2018;91:3\u201316.","journal-title":"HLA"},{"key":"52_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","volume":"6","author":"KD White","year":"2018","unstructured":"White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, et al. SJS\/TEN 2017: building multidisciplinary networks to drive science and translation. J Allergy Clin Immunol Pract. 2018;6:38\u201369.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"52_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1528-1167.2009.02269.x","volume":"51","author":"H Ikeda","year":"2010","unstructured":"Ikeda H, Takahashi Y, Yamazaki E, Fujiwara T, Kaniwa N, Saito Y, et al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia. 2010;51:297\u2013300.","journal-title":"Epilepsia"},{"key":"52_CR24","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","volume":"364","author":"P Chen","year":"2011","unstructured":"Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364:1126\u201333.","journal-title":"N Engl J Med"},{"key":"52_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s11096-013-9777-9","volume":"35","author":"S Tiamkao","year":"2013","unstructured":"Tiamkao S, Jitpimolmard J, Sawanyawisuth K, Jitpimolmard S. Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand. Int J Clin Pharm. 2013;35:608\u201312.","journal-title":"Int J Clin Pharm"},{"key":"52_CR26","doi-asserted-by":"publisher","first-page":"e94294","DOI":"10.1371\/journal.pone.0094294","volume":"9","author":"S Saokaew","year":"2014","unstructured":"Saokaew S, Tassaneeyakul W, Maenthaisong R, Chaiyakunapruk N. Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS\/TEN in Thai population. PLoS ONE. 2014;9:e94294.","journal-title":"PLoS ONE"},{"key":"52_CR27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/FPC.0000000000000319","volume":"28","author":"HY Chong","year":"2018","unstructured":"Chong HY, Lim YH, Prawjaeng J, Tassaneeyakul W, Mohamed Z, Chaiyakunapruk N. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Malaysian population. Pharm Genom. 2018;28:56\u201367.","journal-title":"Pharm Genom"},{"issue":"7","key":"52_CR28","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1001\/jamaneurol.2018.0278","volume":"75","author":"Taisei Mushiroda","year":"2018","unstructured":"Mushiroda T, Takahashi Y, Onuma T, Yamamoto Y, Kamei T, Hoshida T, et al. Association of HLA-A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population. JAMA Neurology. 2018;75:842\u20139.","journal-title":"JAMA Neurology"},{"key":"52_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/ACI.0b013e3282370c5f","volume":"7","author":"WH Chung","year":"2007","unstructured":"Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol. 2007;7:317\u201323.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"52_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-12-118","volume":"12","author":"R Somkrua","year":"2011","unstructured":"Somkrua R, Eickman EE, Saokaew S, Lohitnavy M, Chaiyakunapruk N. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet. 2011;12:118.","journal-title":"BMC Med Genet"},{"key":"52_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.18433\/J39S3T","volume":"18","author":"W Tangamornsuksan","year":"2015","unstructured":"Tangamornsuksan W, Lohitnavy O, Kongkaew C, Chaiyakunapruk N, Reisfeld B, Scholfield NC, et al. Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis. J Pharm Pharm Sci. 2015;18:68\u201376.","journal-title":"J Pharm Pharm Sci"},{"key":"52_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1212\/WNL.0000000000003453","volume":"88","author":"CB Chen","year":"2017","unstructured":"Chen CB, Hsiao YH, Wu T, Hsih MS, Tassaneeyakul W, Jorns TP, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology. 2017;88:78\u201386.","journal-title":"Neurology"},{"key":"52_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18433\/J36S7D","volume":"21","author":"W Tangamornsuksan","year":"2018","unstructured":"Tangamornsuksan W, Scholfield N, Lohitnavy M. Association between HLA genotypes and oxcarbazepine-induced cutaneous adverse drug reactions: a systematic review and meta-analysis. J Pharm Pharm Sci. 2018;21:1\u201318.","journal-title":"J Pharm Pharm Sci"},{"issue":"jul09 1","key":"52_CR34","first-page":"bcr2013203163","volume":"2014","author":"J. P. Rijal","year":"2014","unstructured":"Rijal JP, Pompa T, Giri S, Bhatt VR. A case of toxic epidermal necrolysis caused by trimethoprim-sulfamethoxazole. BMJ Case Rep. 2014;2014:bcr2013203163.","journal-title":"Case Reports"},{"key":"52_CR35","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0161-6420(95)30810-X","volume":"102","author":"AJ Flach","year":"1995","unstructured":"Flach AJ, Smith RE, Fraunfelder FT. Stevens-Johnson syndrome associated with methazolamide treatment reported in two Japanese-American women. Ophthalmology. 1995;102:1677\u201380.","journal-title":"Ophthalmology"},{"key":"52_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1001\/archopht.116.1.117","volume":"116","author":"JB Cotter","year":"1998","unstructured":"Cotter JB. Methazolamide-induced Stevens-Johnson syndrome: a warning! Arch Ophthalmol (Chic, Ill: 1960). 1998;116:117.","journal-title":"Arch Ophthalmol (Chic, Ill: 1960)"},{"key":"52_CR37","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1346-8138.2010.00921.x","volume":"38","author":"Y Her","year":"2011","unstructured":"Her Y, Kil MS, Park JH, Kim CW, Kim SS. Stevens-Johnson syndrome induced by acetazolamide. J Dermatol. 2011;38:272\u20135.","journal-title":"J Dermatol"},{"key":"52_CR38","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/jama.1966.03100080131046","volume":"195","author":"OM Carroll","year":"1966","unstructured":"Carroll OM, Bryan PA, Robinson RJ. Stevens-Johnson syndrome associated with long-acting sulfonamides. JAMA. 1966;195:691\u20133.","journal-title":"JAMA"},{"key":"52_CR39","doi-asserted-by":"publisher","first-page":"623","DOI":"10.4103\/0301-4738.158073","volume":"63","author":"Y Xu","year":"2015","unstructured":"Xu Y, Wu M, Sheng F, Sun Q. Methazolamide-induced toxic epidermal necrolysis in a Chinese woman with HLA-B5901. Indian J Ophthalmol. 2015;63:623\u20134.","journal-title":"Indian J Ophthalmol"},{"key":"52_CR40","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/ijd.12651","volume":"54","author":"C Shu","year":"2015","unstructured":"Shu C, Shu D, Tie D, Yu M, Zhang R, Wang T, et al. Toxic epidermal necrolysis induced by methazolamide in a Chinese-Korean man carrying HLA-B*59:01. Int J Dermatol. 2015;54:1242\u20135.","journal-title":"Int J Dermatol"},{"key":"52_CR41","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/archopht.1997.01100150552021","volume":"115","author":"S Shirato","year":"1997","unstructured":"Shirato S, Kagaya F, Suzuki Y, Joukou S. Stevens-Johnson syndrome induced by methazolamide treatment. Arch Ophthalmol (Chic, Ill: 1960). 1997;115:550\u20133.","journal-title":"Arch Ophthalmol (Chic, Ill: 1960)"},{"key":"52_CR42","first-page":"2241","volume":"41","author":"JI Moon","year":"2000","unstructured":"Moon JI, Seo JH, Park CK. Association of HLA type with Stevens-Johnson syndrome induced by methazolamide treatment. J Korean Ophthalmol Soc. 2000;41:2241.","journal-title":"J Korean Ophthalmol Soc"},{"key":"52_CR43","first-page":"561","volume":"43","author":"KH Sung","year":"2005","unstructured":"Sung KH, Jeong Y, Choi HU, Lee SK. Two cases of HLA-B59(+) Stevens-Johnson syndrome-toxic epidermal necrolysis associated with methazolamide treatment. Korean J Dermatol. 2005;43:561\u20133.","journal-title":"Korean J Dermatol"},{"key":"52_CR44","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2217\/pgs.10.54","volume":"11","author":"SH Kim","year":"2010","unstructured":"Kim SH, Kim M, Lee KW, Kim SH, Kang HR, Park HW, et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis. Pharmacogenomics. 2010;11:879\u201384.","journal-title":"Pharmacogenomics"},{"key":"52_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/jidsymp.2015.6","volume":"17","author":"F Yang","year":"2015","unstructured":"Yang F, Yang Y, Zhu Q, Chen SA, Fu X, Yan S, et al. Research on susceptible genes and immunological pathogenesis of cutaneous adverse drug reactions in Chinese Hans. J Investig Dermatol Symp Proc. 2015;17:29\u201331.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"52_CR46","first-page":"83","volume":"16","author":"F Yang","year":"2016","unstructured":"Yang F, Xuan J, Chen J, Zhong H, Luo H, Zhou P, et al. HLA-B*59:01: a marker for Stevens-Johnson syndrome\/toxic epidermal necrolysis caused by methazolamide in Han Chinese. Pharm J. 2016;16:83\u20137.","journal-title":"Pharm J"},{"key":"52_CR47","doi-asserted-by":"publisher","first-page":"645","DOI":"10.5021\/ad.2014.26.5.645","volume":"26","author":"M Cheon","year":"2014","unstructured":"Cheon M, Lee YB, Yu DS, Kim JW. Toxic epidermal necrolysis in a patient with HLA-B*5901 haplotype caused by topical and oral carbonic anhydrase inhibitors. Ann Dermatol. 2014;26:645\u20136.","journal-title":"Ann Dermatol"},{"key":"52_CR48","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/sim.2010","volume":"24","author":"A Thakkinstian","year":"2005","unstructured":"Thakkinstian A, McElduff P, D\u2019Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med. 2005;24:1291\u2013306.","journal-title":"Stat Med"},{"key":"52_CR49","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jclinepi.2005.01.001","volume":"58","author":"K Smits","year":"2005","unstructured":"Smits K, Schouten J, Smits L, Stelma F, Nelemans P, Prins M. A review on the design and reporting of studies on drug-gene interaction. J Clin Epidemiol. 2005;58:651\u20134.","journal-title":"J Clin Epidemiol"},{"key":"52_CR50","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2011. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp ."},{"key":"52_CR51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00787-010-0087-7","volume":"19","author":"M Szumilas","year":"2010","unstructured":"Szumilas M. Explaining odds ratios. J Can Acad Child Adolescent Psychiatry. 2010;19:227\u20139.","journal-title":"J Can Acad Child Adolescent Psychiatry"},{"key":"52_CR52","first-page":"1379","volume":"54","author":"RA Callcut","year":"2009","unstructured":"Callcut RA, Branson RD. How to read a review paper. Respir Care. 2009;54:1379\u201385.","journal-title":"Respir Care"},{"key":"52_CR53","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1080\/17453670710014284","volume":"78","author":"M Zlowodzki","year":"2007","unstructured":"Zlowodzki M, Poolman RW, Kerkhoffs GM, Tornetta P 3rd, Bhandari M. How to interpret a meta-analysis and judge its value as a guide for clinical practice. Acta Orthop. 2007;78:598\u2013609.","journal-title":"Acta Orthop"},{"key":"52_CR54","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"52_CR55","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"J Higgins","year":"2002","unstructured":"Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"52_CR56","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"J Higgins","year":"2003","unstructured":"Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"52_CR57","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","volume":"53","author":"JA Sterne","year":"2000","unstructured":"Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53:1119\u201329.","journal-title":"J Clin Epidemiol"},{"key":"52_CR58","unstructured":"The Allele Frequency Net Database [Internet]. 2015 [cited December 20, 2017]. Available from: http:\/\/www.allelefrequencies.net ."},{"issue":"Database issue","key":"52_CR59","doi-asserted-by":"publisher","first-page":"D784","DOI":"10.1093\/nar\/gku1166","volume":"43","author":"FF Gonzalez-Galarza","year":"2015","unstructured":"Gonzalez-Galarza FF, Takeshita LY, Santos EJ, Kempson F, Maia MH, da Silva AL, et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res. 2015;43(Database issue):D784\u20138.","journal-title":"Nucleic Acids Res"},{"key":"52_CR60","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/jamadermatol.2017.6484","volume":"154","author":"W Tangamornsuksan","year":"2018","unstructured":"Tangamornsuksan W, Lohitnavy M. Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions: a systematic review and meta-analysis. JAMA Dermatol. 2018;154:441\u20136.","journal-title":"JAMA Dermatol"},{"key":"52_CR61","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/FPC.0000000000000306","volume":"27","author":"T Tempark","year":"2017","unstructured":"Tempark T, Satapornpong P, Rerknimitr P, Nakkam N, Saksit N, Wattanakrai P, et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. Pharm Genom. 2017;27:429\u201337.","journal-title":"Pharm Genom"},{"key":"52_CR62","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1346-8138.2009.00646.x","volume":"27","author":"JW Kim","year":"2009","unstructured":"Kim JW, Shin SY. Toxic epidermal necrolysis and Stevens-Johnson syndrome caused by topical ophthalmic use of dorzolamid. Korean. J Dermatol. 2009;27:317\u201321.","journal-title":"J Dermatol"},{"key":"52_CR63","first-page":"216","volume":"39","author":"JHLS Lee","year":"1998","unstructured":"Lee JHLS, Kim YH. A case of Stevens-Johnson syndrome after acetazolamide use. J Korean Ophthalmol Soc. 1998;39:216\u201320.","journal-title":"J Korean Ophthalmol Soc"},{"key":"52_CR64","doi-asserted-by":"publisher","first-page":"260","DOI":"10.5021\/ad.2008.20.4.260","volume":"20","author":"JS Chun","year":"2008","unstructured":"Chun JS, Yun SJ, Lee JB, Kim SJ, Won YH, Lee SC. Toxic epidermal necrolysis induced by the topical carbonic anhydrase inhibitors brinzolamide and dorzolamide. Ann Dermatol. 2008;20:260\u20132.","journal-title":"Ann Dermatol"},{"key":"52_CR65","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1399-0039.2005.00386.x","volume":"65","author":"KW Lee","year":"2005","unstructured":"Lee KW, Oh DH, Lee C, Yang SY. Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens. 2005;65:437\u201347.","journal-title":"Tissue Antigens"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-018-0052-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-018-0052-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-018-0052-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T20:59:42Z","timestamp":1684616382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-018-0052-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,21]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["52"],"URL":"https:\/\/doi.org\/10.1038\/s41397-018-0052-2","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,21]]},"assertion":[{"value":"23 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}